Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Depreciation and Depletion (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Depreciation and Depletion readings, the most recent being $11000.0 for Q1 2026.

  • Quarterly Depreciation and Depletion changed 0.0% to $11000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $43000.0 through Mar 2026, up 2.38% year-over-year, with the annual reading at $43000.0 for FY2025, 10.26% up from the prior year.
  • Depreciation and Depletion hit $11000.0 in Q1 2026 for DiaMedica Therapeutics, roughly flat from $11000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $18000.0 in Q3 2025 and bottomed at $3000.0 in Q2 2025.
  • Average Depreciation and Depletion over 5 years is $8705.9, with a median of $8000.0 recorded in 2023.
  • Peak annual rise in Depreciation and Depletion hit 80.0% in 2025, while the deepest fall reached 70.0% in 2025.
  • DiaMedica Therapeutics' Depreciation and Depletion stood at $6000.0 in 2022, then surged by 33.33% to $8000.0 in 2023, then surged by 37.5% to $11000.0 in 2024, then changed by 0.0% to $11000.0 in 2025, then changed by 0.0% to $11000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Depreciation and Depletion are $11000.0 (Q1 2026), $11000.0 (Q4 2025), and $18000.0 (Q3 2025).